In this study, the therapeutic drug monitoring of teicoplanin is carried out among children to obtain the drug concentration, clinical efficacy and safety data of children patients in different gender and age groups. Then we analyze the relationship between blood drug concentration and efficacy and safety, and provide recommendations for the treatment window of teicoplanin in Chinese children.

Inclusion Criteria:

• Teicoplanin was administered intravenously;
• Teicoplanin was used for therapeutic purposes;
• Age:≤18 years;
• Clinician confirms and plans to diagnose the patient with gram-positive coccus infection;
• Patients with therapeutic concentration monitoring of teicoplanin.

Exclusion Criteria:

• Teicoplanin was administered non-intravenously;
• Teicoplanin was used for prophylactic purposes;
• Patients without therapeutic concentration monitoring of teicoplanin;
• Patients who die within 24 hours of the use of teicoplanin；
• The blood concentrations of the patient was not approved by the quality control center.

Children with gram-positive coccus infection